BioAtla IPO Presentation Deck

BA3071: Global Strategic Collaboration BeiGene Demonstrated BeiGene Commitment • BeiGene holds an exclusive global license to BA3071 • BioAtla has received $25 million in upfront payments & reimbursement • BioAtla eligible to receive up to $225.5 million for subsequent regulatory and development milestones • BioAtla eligible to receive tiered royalties of up to low 20's on worldwide sales Note: 'Equivalent to 10mg/kg of ipilimumab Clinical Development Timeline bicatla Expected Phase 1 dose escalation trial in 2021 • Doses of 7mg Q3W to 700mg Q3W¹ as monotherapy and in combination with tislelizumab . Tislelizumab is an anti-PD-1 antibody in late-stage development by BeiGene Collaboration & Support • BeiGene leads Development, Manufacturing and Commercialization activities 24

View entire presentation